BLCO

Bausch + Lomb Corporation

19.97

Top Statistics
Market Cap 7 B Forward PE 23.76 Revenue Growth 18.80 %
Current Ratio 1.57 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -7.86 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 17.96 Enterprise / Revenue 2.44 Price To Sales Trailing12 Months 1.53
Profitability
Profit Margins -7.86 % Operating Margins 5.44 %
Balance Sheet
Total Cash 329 M Total Cash Per Share 0.9340 Total Debt 4 B
Total Debt To Equity 69.49 Current Ratio 1.57 Book Value Per Share 18.71
All Measures
Short Ratio 161.00 % Message Board Id finmb_1678122959 Shares Short Prior Month 1 M
Return On Equity -0.0523 City Vaughan Uuid 2dfa4f41-10d0-3324-be8e-f99a01abce5b
Previous Close 19.75 First Trade Date Epoch Utc 1 B Book Value 18.71
Beta 0.4600 Total Debt 4 B Volume 126868
Price To Book 1.07 Fifty Two Week Low 13.16 Total Cash Per Share 0.9340
Total Revenue 4 B Shares Short Previous Month Date 1 B Target Median Price 21.50
Max Age 86400 Recommendation Mean 2.20 Sand P52 Week Change 0.3133
Operating Margins 5.44 % Target Mean Price 21.43 Net Income To Common -368000000
Ask 20.50 Short Percent Of Float 0.0234 Implied Shares Outstanding 359 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 312380
Average Volume10days 312380 Total Cash 329 M Next Fiscal Year End 1 B
Revenue Per Share 13.33 Held Percent Insiders 0.8847 Ebitda Margins 13.56 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 19.75 Target Low Price 18.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 19.80 Open 19.73 Free Cashflow 137 M
State ON Dividend Yield 0.00 % Return On Assets 0.0089
Time Zone Short Name EST Trailing Eps -1.04 Day Low 19.72
Address1 520 Applewood Crescent Shares Outstanding 352 M Price Hint 2
Target High Price 26.00 Website https://www.bausch.com 52 Week Change 0.2959
Average Volume 647071 Forward Eps 1.19 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 72.20 % Is_sp_500 False
Regular Market Day High 20.05 Profit Margins -7.86 % Debt To Equity 69.49
Fifty Two Week High 21.69 Day High 20.05 Shares Short 967275
Regular Market Open 19.73 Industry Key medical-instruments-supplies Bid 20.05
Earnings Growth 0.00 % Enterprise To Revenue 2.44 Revenue Growth 18.80 %
Shares Percent Shares Out 0.0027 Operating Cashflow 225 M Currency USD
Time Zone Full Name America/New_York Market Cap 7 B Is_nasdaq_100 False
Zip L4K 4B4 Quote Type EQUITY Industry Medical Instruments & Supplies
Long Name Bausch + Lomb Corporation Regular Market Day Low 19.72 Held Percent Institutions 0.1091
Current Price 19.97 Enterprise To Ebitda 17.96 Financial Currency USD
Current Ratio 1.57 Gross Margins 60.89 % Industry Disp Medical Instruments & Supplies
Number Of Analyst Opinions 14 Country Canada Float Shares 351 M
Two Hundred Day Average 16.71 Enterprise Value 11 B Price To Sales Trailing12 Months 1.53
Forward PE 23.76 Regular Market Volume 126868 Ebitda 635 M
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.

It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.

The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases.

The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery.

The company sells its products and services through direct sales forces and independent distributors.

Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada.

Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.